{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T21:04:53Z","timestamp":1779311093290,"version":"3.51.4"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3,1]]},"DOI":"10.1093\/jac\/dkx452","type":"journal-article","created":{"date-parts":[[2017,11,4]],"date-time":"2017-11-04T20:09:33Z","timestamp":1509826173000},"page":"772-778","source":"Crossref","is-referenced-by-count":14,"title":["Comparative analysis of neutropenia in patients receiving prolonged treatment with ceftaroline"],"prefix":"10.1093","volume":"73","author":[{"given":"R Brigg","family":"Turner","sequence":"first","affiliation":[{"name":"School of Pharmacy, Pacific University, 222 SE 8th Ave Suite 451, Hillsboro, OR, USA"},{"name":"Department of Pharmacy, Legacy Health, 2801 N Gantenbein Ave, Portland, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D Erin","family":"Wilson","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Pacific University, 222 SE 8th Ave Suite 451, Hillsboro, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Saedi-Kwon","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Pacific University, 222 SE 8th Ave Suite 451, Hillsboro, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Legacy Health, 2801 N Gantenbein Ave, Portland, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Won","sequence":"additional","affiliation":[{"name":"Department of Medicine, Legacy Health, 2801 N Gantenbein Ave, Portland, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Legacy Health, 2801 N Gantenbein Ave, Portland, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Schwartz","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Pacific University, 222 SE 8th Ave Suite 451, Hillsboro, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,12,8]]},"reference":[{"key":"key\n\t\t\t\t20180216030023_dkx452-B1","doi-asserted-by":"crossref","first-page":"S344","DOI":"10.1086\/533590","article-title":"Epidemiology of methicillin-resistant Staphylococcus aureus","volume":"46","author":"Boucher","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1128\/CMR.00042-09","article-title":"Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications","volume":"23","author":"Howden","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B3","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/jac\/dkr066","article-title":"Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure","volume":"66","author":"Kelley","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B4","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B5","doi-asserted-by":"crossref","first-page":"4.","DOI":"10.3410\/M4-4","article-title":"Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates ('the MIC Creep'): implications for therapy","volume":"4","author":"Dhand","year":"2012","journal-title":"F1000 Med Rep"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B6","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/jac\/dkm258","article-title":"Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05","volume":"60","author":"Steinkraus","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B7","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/FTD.0000000000000222","article-title":"Daptomycin: physicochemical, analytical, and pharmacological properties","volume":"37","author":"T\u00f3toli","year":"2015","journal-title":"Ther Drug Monit"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B8","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s40265-016-0654-4","article-title":"Ceftaroline fosamil: a review in complicated skin and soft tissue infections and community-acquired pneumonia","volume":"76","author":"Scott","year":"2016","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B9","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1086\/657313","article-title":"Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia","volume":"51","author":"File","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B10","doi-asserted-by":"crossref","first-page":"iii19","DOI":"10.1093\/jac\/dkr096","article-title":"FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"File","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B11","doi-asserted-by":"crossref","first-page":"iii33","DOI":"10.1093\/jac\/dkr097","article-title":"FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"Low","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B12","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/jac\/dkq254","article-title":"CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Corey","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B13","doi-asserted-by":"crossref","first-page":"iv67","DOI":"10.1093\/jac\/dkq256","article-title":"Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Corrado","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B14","doi-asserted-by":"crossref","first-page":"iv53","DOI":"10.1093\/jac\/dkq255","article-title":"CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Wilcox","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B15","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/phar.1435","article-title":"High incidence of discontinuations due to adverse events in patients treated with ceftaroline","volume":"34","author":"Jain","year":"2014","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B16","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/jcpt.12062","article-title":"Ceftaroline\u2014a cause for neutropenia","volume":"38","author":"Rimawi","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B17","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.2146\/ajhp130474","article-title":"A case of profound neutropenia and agranulocytosis associated with off-label use of ceftaroline","volume":"71","author":"Yam","year":"2014","journal-title":"Am J Health Syst Pharm"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B18","doi-asserted-by":"crossref","first-page":"ofx084","DOI":"10.1093\/ofid\/ofx084","article-title":"Ceftaroline for severe methicillin-resistant Staphylococcus aureus infections: a systematic review","volume":"4","author":"Cosimi","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B19","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/jac\/dks006","article-title":"Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy","volume":"67","author":"Ho","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s10156-012-0449-9","article-title":"The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients","volume":"19","author":"Lin","year":"2013","journal-title":"J Infect Chemother"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B21","doi-asserted-by":"crossref","DOI":"10.1080\/1120009X.2017.1351729","article-title":"Ceftaroline for the treatment of osteomyelitis caused by methicillin-resistant Staphylococcus aureus: a case series","author":"Lalikian","year":"2017","journal-title":"J Chemother"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B22","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/jac\/dkw062","article-title":"High incidence of neutropenia in patients with prolonged ceftaroline exposure","volume":"71","author":"Furtek","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B23","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1177\/1060028016667583","article-title":"High incidence of adverse effects with extended use of ceftaroline","volume":"50","author":"Dellabella","year":"2016","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B24","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/AAC.01471-15","article-title":"Neutropenia associated with long-term ceftaroline use","volume":"60","author":"LaVie","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B25","author":"Saedi-Kwon"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B26","first-page":"962","volume-title":"Drug-Induced Diseases Prevention, Detection, and Management","author":"Fausel","year":"2010","edition":"2nd edn"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B27","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4065\/74.3.290","article-title":"The penicillins","volume":"74","author":"Wright","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B29","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B30","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/cid\/ciu301","article-title":"Comparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible Staphylococcus aureus infections in the outpatient setting","volume":"59","author":"Youngster","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B31","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Statist Med"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B32","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1097\/MLR.0b013e31806518ac","article-title":"Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases","volume":"45","author":"Curtis","year":"2007","journal-title":"Med Care"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B33","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/asheducation.V2012.1.174.3798251","article-title":"How to approach neutropenia","volume":"2012","author":"Boxer","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B34","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/0897190014546115","article-title":"Nonchemotherapy drug-induced neutropenia and agranulocytosis: could medications be the culprit?","volume":"27","author":"Pick","year":"2014","journal-title":"J Pharm Pract"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B35","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1586\/eci.10.53","article-title":"Immunological aspects of nonimmediate reactions to \u03b2-lactam antibiotics","volume":"6","author":"Rodilla","year":"2010","journal-title":"Expert Rev Clin Immunol"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B36","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1001\/archinte.159.6.607","article-title":"Incidence of \u03b2-lactam-induced delayed hypersensitivity and neutropenia during treatment of infective endocarditis","volume":"159","author":"Olaison","year":"1999","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B37","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1128\/AAC.31.11.1657","article-title":"Effects of \u03b2-lactam antibiotics on proliferating eucaryotic cells","volume":"31","author":"Neftel","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B38","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/cid\/cit023","article-title":"Neutropenia associated with prolonged daptomycin use","volume":"56","author":"Knoll","year":"2013","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B39","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0163-4453(05)80002-7","article-title":"High incidence of vancomycin-associated leucopenia and neutropenia in a cardiothoracic surgical unit","volume":"22","author":"Morris","year":"1991","journal-title":"J Infect"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B40","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1345\/aph.1G436","article-title":"Epidemiology of vancomycin-induced neutropenia in patients receiving home intravenous infusion therapy","volume":"40","author":"Pai","year":"2006","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B41","doi-asserted-by":"crossref","first-page":"ii45","DOI":"10.1093\/jac\/dkg253","article-title":"Safety and tolerability of linezolid","volume":"51","author":"French","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B42","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s15010-007-6197-6","article-title":"Linezolid-related pancytopenia in organ-transplant patients: report of two cases","volume":"35","author":"Faguer","year":"2007","journal-title":"Infection"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B43","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s11096-013-9814-8","article-title":"Filgrastim therapy in a child with neutropenia induced by linezolid","volume":"35","author":"Hern\u00e1ndez Segurado","year":"2013","journal-title":"Int J Clin Pharm"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B44","doi-asserted-by":"crossref","first-page":"S186","DOI":"10.1097\/01.inf.0000087021.20838.d9","article-title":"Hematologic effects of linezolid in young children","volume":"22","author":"Meissner","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B45","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/phar.1824","article-title":"Effect of linezolid on hematologic recovery in newly diagnosed acute myeloid leukemia patients following induction chemotherapy","volume":"36","author":"Nedved","year":"2016","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.02015-16","article-title":"Multicenter observational study of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections","volume":"61","author":"Zasowski","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B47","first-page":"1","article-title":"Side effects of rifampicin. A clinical study","volume":"82","author":"Mattson","year":"1973","journal-title":"Scand J Respir Dis Suppl"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B48","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1136\/bmj.280.6221.1069","article-title":"Neutropenia with each standard antituberculosis drug in the same patient","volume":"280","author":"Jenkins","year":"1980","journal-title":"Br Med J"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B49","doi-asserted-by":"crossref","first-page":"ofu046","DOI":"10.1093\/ofid\/ofu046","article-title":"Ceftaroline in combination with trimethoprim-sulfamethoxazole for salvage therapy of methicillin-resistant Staphylococcus aureus bacteremia and endocarditis","volume":"1","author":"Fabre","year":"2014","journal-title":"Open Forum Infect Dis"},{"key":"key\n\t\t\t\t20180216030023_dkx452-B50","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1128\/AAC.02371-13","article-title":"Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy","volume":"58","author":"Casapao","year":"2014","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/73\/3\/772\/23823675\/dkx452.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T03:58:43Z","timestamp":1603252723000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/73\/3\/772\/4717792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,8]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,12,8]]},"published-print":{"date-parts":[[2018,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkx452","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,3]]},"published":{"date-parts":[[2017,12,8]]}}}